Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion

• Main Authors: Linlei Zhang (Author), Shasha Xu (Author), Xiaoxiao Wu (Author), Jiaou Chen (Author), Xiaoling Guo (Author), Yungang Cao (Author), Zheng Zhang (Author), Jueyue Yan (Author), Jianhua Cheng (Author), Zhao Han (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Recombinant tissue plasminogen activator (rt-PA) is used to treat acute ischemic stroke but is only effective if administered within 4.5 h after stroke onset. Delayed rt-PA treatment causes blood-brain barrier (BBB) disruption and hemorrhagic transformation. The compound 2-(-2-benzofuranyl)-2-imidaz...